Amgen Hiding Biosimilar Info, Genentech Suit Says

Law360, New York (February 16, 2017, 8:32 PM EST) -- Amgen is hypocritically withholding information about its proposed biosimilar of cancer drug Avastin and thereby undercutting potential patent litigation, Genentech charged in a complaint filed Wednesday in Delaware federal court.

Genentech Inc.’s complaint accuses Amgen Inc. of short-circuiting a section of the Biologics Price Competition and Innovation Act known as the “patent dance.” The dance directs biosimilar makers to disclose approval applications and “other information” about manufacturing, but Amgen has only divulged its application, according to Genentech.

That amounts to “ignoring the express statutory language” of...
To view the full article, register now.